Compare Aventis Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs NOVARTIS - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA NOVARTIS SANOFI INDIA/
NOVARTIS
 
P/E (TTM) x 43.6 2,112.6 2.1% View Chart
P/BV x 8.7 28.0 31.2% View Chart
Dividend Yield % 1.0 1.6 63.3%  

Financials

 SANOFI INDIA   NOVARTIS
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
NOVARTIS
Mar-19
SANOFI INDIA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs6,840980 698.0%   
Low Rs4,630600 771.4%   
Sales per share (Unadj.) Rs1,203.1198.7 605.4%  
Earnings per share (Unadj.) Rs165.321.0 788.2%  
Cash flow per share (Unadj.) Rs209.922.3 942.9%  
Dividends per share (Unadj.) Rs84.0010.00 840.0%  
Dividend yield (eoy) %1.51.3 115.7%  
Book value per share (Unadj.) Rs963.6307.5 313.4%  
Shares outstanding (eoy) m23.0324.69 93.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.84.0 119.9%   
Avg P/E ratio x34.737.7 92.1%  
P/CF ratio (eoy) x27.335.5 77.0%  
Price / Book Value ratio x6.02.6 231.6%  
Dividend payout %50.847.7 106.6%   
Avg Mkt Cap Rs m132,07819,508 677.1%   
No. of employees `0003.30.6 568.2%   
Total wages/salary Rs m4,0681,171 347.4%   
Avg. sales/employee Rs Th8,393.88,445.4 99.4%   
Avg. wages/employee Rs Th1,232.42,015.7 61.1%   
Avg. net profit/employee Rs Th1,153.0891.0 129.4%   
INCOME DATA
Net Sales Rs m27,7084,907 564.7%  
Other income Rs m897783 114.6%   
Total revenues Rs m28,6055,689 502.8%   
Gross profit Rs m6,235123 5,077.4%  
Depreciation Rs m1,02732 3,229.6%   
Interest Rs m716 44.0%   
Profit before tax Rs m6,098858 711.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,292340 674.1%   
Profit after tax Rs m3,806518 735.2%  
Gross profit margin %22.52.5 899.1%  
Effective tax rate %37.639.6 94.8%   
Net profit margin %13.710.6 130.2%  
BALANCE SHEET DATA
Current assets Rs m15,9228,055 197.7%   
Current liabilities Rs m6,2351,850 337.0%   
Net working cap to sales %35.0126.4 27.6%  
Current ratio x2.64.4 58.7%  
Inventory Days Days6445 141.4%  
Debtors Days Days2134 61.5%  
Net fixed assets Rs m7,539150 5,032.7%   
Share capital Rs m230123 186.4%   
"Free" reserves Rs m21,9627,469 294.1%   
Net worth Rs m22,1927,592 292.3%   
Long term debt Rs m00-   
Total assets Rs m29,8399,824 303.7%  
Interest coverage x872.154.9 1,587.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.5 185.9%   
Return on assets %12.85.4 235.3%  
Return on equity %17.26.8 251.5%  
Return on capital %27.511.5 239.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,58758 13,171.9%   
Fx outflow Rs m7,1451,326 538.7%   
Net fx Rs m442-1,269 -34.8%   
CASH FLOW
From Operations Rs m3,739-1,943 -192.5%  
From Investments Rs m-7312,742 -26.7%  
From Financial Activity Rs m-1,972-298 661.3%  
Net Cashflow Rs m1,036501 206.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 75.0 80.5%  
Indian inst/Mut Fund % 14.4 2.0 720.0%  
FIIs % 14.6 1.6 912.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.5 48.8%  
Shareholders   15,184 41,647 36.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   BIOCON   CADILA HEALTHCARE  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 127 Points Higher; Auto Stocks Witness Huge Buying(Closing)

Share markets in India continued to trade on a positive note during closing hours today and ended their session marginally higher.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

My View on ITC(Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

Why India's Drone Revolution is a 4x Profit Opportunity(Profit Hunter)

Oct 16, 2020

My research on India's leading defence companies brought me to one major player in drone manufacturing.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Oct 23, 2020 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - CIPLA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS